Use: Labeled indications
- INDICATIONS AND USAGE DIFLUCAN (fluconazole) is indicated for the treatment of: 1.
Full indications and usage US FDA label
INDICATIONS AND USAGE DIFLUCAN (fluconazole) is indicated for the treatment of: 1. Vaginal candidiasis (vaginal yeast infections due to Candida). 2. Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, DIFLUCAN was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. 3.
Cryptococcal meningitis. Before prescribing DIFLUCAN (fluconazole) for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing DIFLUCAN to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: DIFLUCAN is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy.
Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.
Contraindications
- Hypersensitivity to fluconazole
- Coadministration of QT-prolonging CYP3A4 substrates (erythromycin, pimozide, quinidine)
Contraindications (US label) US FDA label
CONTRAINDICATIONS DIFLUCAN (fluconazole) is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. There is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. Caution should be used in prescribing DIFLUCAN to patients with hypersensitivity to other azoles.
Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and PRECAUTIONS.)
Dosing: Adult
- Vaginal candidiasis: 150 mg once
- Oropharyngeal candidiasis: 200 mg day 1, then 100 mg daily for at least 2 weeks
- Esophageal candidiasis: 200 mg day 1, then 100 mg daily (up to 400 mg/day)
- Cryptococcal meningitis: 400 mg day 1, then 200 mg daily (400 mg daily by judgment)
- Prophylaxis in bone marrow transplant: 400 mg daily
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Dosage and Administration in Adults: Single Dose Vaginal candidiasis: The recommended dosage of DIFLUCAN for vaginal candidiasis is 150 mg as a single oral dose. Multiple Dose SINCE ORAL ABSORPTION IS RAPID AND ALMOST COMPLETE, THE DAILY DOSE OF DIFLUCAN (FLUCONAZOLE) IS THE SAME FOR ORAL (TABLETS AND SUSPENSION) AND INTRAVENOUS ADMINISTRATION.
In general, a loading dose of twice the daily dose is recommended on the first day of therapy to result in plasma concentrations close to steady-state by the second day of therapy. The daily dose of DIFLUCAN for the treatment of infections other than vaginal candidiasis should be based on the infecting organism and the patient's response to therapy.
Treatment should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection. Patients with AIDS and cryptococcal meningitis or recurrent oropharyngeal candidiasis usually require maintenance therapy to prevent relapse.
Oropharyngeal candidiasis: The recommended dosage of DIFLUCAN for oropharyngeal candidiasis is 200 mg on the first day, followed by 100 mg once daily. Clinical evidence of oropharyngeal candidiasis generally resolves within several days, but treatment should be continued for at least 2 weeks to decrease the likelihood of relapse.
Esophageal candidiasis: The recommended dosage of DIFLUCAN for esophageal candidiasis is 200 mg on the first day, followed by 100 mg once daily. Doses up to 400 mg/day may be used, based on medical judgment of the patient's response to therapy. Patients with esophageal candidiasis should be treated for a minimum of three weeks and for at least two weeks following resolution of symptoms.
Systemic Candida infections: For systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia, optimal therapeutic dosage and duration of therapy have not been established. In open, noncomparative studies of small numbers of patients, doses of up to 400 mg daily have been used. Urinary tract infections and peritonitis: For the treatment of Candida urinary tract infections and peritonitis, daily doses of 50 to 200 mg have been used in open, noncomparative studies of small numbers of patients.
Cryptococcal meningitis: The recommended dosage for treatment of acute cryptococcal meningitis is 400 mg on the first day, followed by 200 mg once daily. A dosage of 400 mg once daily may be used, based on medical judgment of the patient's response to therapy. The recommended duration of treatment for initial therapy of cryptococcal meningitis is 10 to 12 weeks after the cerebrospinal fluid becomes culture negative.
The recommended dosage of DIFLUCAN for suppression of relapse of cryptococcal meningitis in patients with AIDS is 200 mg once daily. Prophylaxis in patients undergoing bone marrow transplantation: The recommended DIFLUCAN daily dosage for the prevention of candidiasis in patients undergoing bone marrow transplantation is 400 mg, once daily.
Patients who are anticipated to have severe granulocytopenia (less than 500 neutrophils cells/mm 3) should start DIFLUCAN prophylaxis several days before the anticipated onset of neutropenia, and continue for 7 days after the neutrophil count rises above 1000 cells/mm 3. Dosage and Administration in Pediatric Patients Oropharyngeal candidiasis: The recommended dosage of DIFLUCAN for oropharyngeal candidiasis in pediatric patients 6 months and older is 6 mg/kg on the first day, followed by 3 mg/kg once daily.
Treatment should be administered for at least 2 weeks to decrease the likelihood of relapse. Esophageal candidiasis: For the treatment of esophageal candidiasis, the recommended dosage of DIFLUCAN in pediatric patients 6 months and older is 6 mg/kg on the first day, followed by 3 mg/kg once daily. Doses up to 12 mg/kg/day may be used, based on medical judgment of the patient’s response to therapy.
Patients with esophageal candidiasis should be treated for a minimum of three weeks and for at least 2 weeks following the resolution of symptoms. Systemic Candida infections: The following dosing regimens in Table 6 are recommended for pediatric patients to achieve systemic exposures similar to adults for the treatment of systemic Candida infections, i.e., to maintain an AUC 0-24 between 400-800 mg*h/L.
Table 6: Recommended Dosing Regimens for the Treatment of Systemic Candida Infections in Pediatric Patients Patient age Dosing regimen 3 months and older A loading dose of 25-mg/kg on the first day (not to exceed 800 mg) followed by 12-mg/kg once daily (not to exceed 400 mg). Birth to 3 months postnatal age and gestational age 30 weeks and above 25-mg/kg on the first day, followed by 12-mg/kg once daily Birth to 3 months postnatal age and gestational age less than 30 weeks 25-mg/kg on the first day, followed by 9-mg/kg once daily Patients with systemic candidiasis should be treated for a minimum of 3 weeks and for at least 2 weeks following the resolution of symptoms.
Dosing in Pediatric Patients on ECMO: The recommended dosage of DIFLUCAN in pediatric patients 3 months and older on ECMO is 35-mg/kg on the first day (not to exceed 800 mg) followed by 12-mg/kg once daily (not to exceed 400 mg). For patients from birth to 3 months postnatal age, and gestational age less than 30 weeks, a loading dose of 35-mg/kg on the first day followed by 9-mg/kg once daily is recommended.
For patients from birth to 3 months postnatal age and gestational age 30 weeks and above, a loading dose of 35-mg/kg on the first day followed by 12-mg/kg once daily is recommended. Cryptococcal meningitis: For the treatment of acute cryptococcal meningitis, the recommended dosage is 12 mg/kg on the first day, followed by 6 mg/kg once daily.
A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy. The recommended duration of treatment for initial therapy of cryptococcal meningitis is 10 to 12 weeks after the cerebrospinal fluid becomes culture negative. For suppression of relapse of cryptococcal meningitis in pediatric patients with AIDS, the recommended dose of DIFLUCAN is 6 mg/kg once daily.
Dosage In Patients With Impaired Renal Function: Fluconazole is cleared primarily by renal excretion as unchanged drug. There is no need to adjust single dose therapy for vaginal candidiasis because of impaired renal function. In patients with impaired renal function who will receive multiple doses of DIFLUCAN, an initial loading dose of 50 mg to 400 mg should be given.
After the loading dose, the daily dose (according to indication) should be based on the following summary: Creatinine Clearance (mL/min) Recommended Dose (%) >50 100 ≤50 (no dialysis) 50 Hemodialysis 100% after each hemodialysis Patients on hemodialysis should receive 100% of the recommended dose after each hemodialysis; on non-dialysis days, patients should receive a reduced dose according to their creatinine clearance. These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses.
Further adjustment may be needed depending upon clinical condition. When serum creatinine is the only measure of renal function available, the following formula (based on sex, weight, and age of the patient) should be used to estimate the creatinine clearance in adults: Males: Weight (kg) × (140 – age) 72 × serum creatinine (mg/100 mL) Females: 0.85 × above value Although the pharmacokinetics of fluconazole has not been studied in pediatric patients with renal insufficiency, dosage reduction in pediatric patients with renal insufficiency should parallel that recommended for adults.
The following formula may be used to estimate creatinine clearance in pediatric patients: K × linear length or height (cm) serum creatinine (mg/100 mL) (Where K=0.55 for pediatric patients older than 1 year and 0.45 for infants.) Administration DIFLUCAN is administered orally. DIFLUCAN can be taken with or without food.
Directions for Mixing the Oral Suspension Prepare a suspension at time of dispensing as follows: tap bottle until all the powder flows freely. To reconstitute, add 24 mL of distilled water or Purified Water (USP) to fluconazole bottle and shake vigorously to suspend powder. Each bottle will deliver 35 mL of suspension. The concentrations of the reconstituted suspensions are as follows: Fluconazole Content per Bottle Concentration of Reconstituted Suspension 350 mg 10 mg/mL 1400 mg 40 mg/mL Note: Shake oral suspension well before using.
Store reconstituted suspension between 30°C (86°F) and 5°C (41°F) and discard unused portion after 2 weeks. Protect from freezing.
Dosing: Altered kidney function
Fluconazole is cleared mainly by the kidneys as unchanged drug. The US label gives a usual loading dose, then 50% of the daily dose at creatinine clearance (CrCl) 50 mL/min or below, and 100% of the dose after each hemodialysis (a 3-hour session lowers levels by about 50%). Single-dose 150 mg for vaginal candidiasis needs no change.
Kidney function measure: Label uses Cockcroft-Gault CrCl (mL/min); cut-off 50.
Show full dosing details
- CrCl ≥60 mL/min
- CrCl >50: usual dose (100%) (label). Single 150 mg dose for vaginal candidiasis: no change at any kidney function.
- CrCl 30–59 mL/min
- CrCl 51–59: usual dose. CrCl ≤50: Give the usual loading dose (50 to 400 mg), then 50% of the usual daily dose (label: CrCl ≤50 without dialysis).
- CrCl 15–29 mL/min
- Give the usual loading dose (50 to 400 mg), then 50% of the usual daily dose (label: CrCl ≤50 without dialysis).
- CrCl <15 mL/min (not on dialysis)
- Give the usual loading dose (50 to 400 mg), then 50% of the usual daily dose (label: CrCl ≤50 without dialysis).
- Hemodialysis (intermittent)
- 100% of the recommended dose after each hemodialysis; on non-dialysis days a reduced dose by CrCl (label). A 3-hour session lowers plasma levels by about 50%.
- Peritoneal dialysis
- No PD dosing in label. For PD-associated fungal peritonitis (ISPD 2022): oral route preferred, 200 mg loading dose then 100 mg daily (Table 6); intraperitoneal 150–200 mg every 24 to 48 hours (Table 5). Specialist input.
- CRRT
- Li 2020 (CRRT review, Table 3): CVVH ultrafiltration 1 L/h, 400 mg every 24 h; ultrafiltration 2.4–3.2 L/h, load 12 mg/kg lean body weight then 6 mg/kg every 24 h. CVVHD dialysate 1 L/h, 800 mg every 24 h; dialysate 4 L/h, load 900 mg then 600 mg every 12 h. CVVHDF (ultrafiltration 2 L/h plus dialysate 1 L/h), 400 mg every 12 h. Dose rises with effluent rate.
- Dialyzable? Yes: a 3-hour hemodialysis session lowers plasma levels by about 50% (label). Protein binding 11% to 12%.
- Monitoring Kidney function for dose; liver tests; QT interval with other QT-prolonging drugs; potassium and magnesium. Levels of interacting drugs (tacrolimus, cyclosporine, warfarin, phenytoin, sulfonylureas).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual weight-based dose (label).
- eGFR 30–59
- Label: not studied in children with kidney impairment, but dose reduction should parallel adults (50% of daily dose if CrCl ≤50, after the loading dose), CrCl by height-based formula (label).
- eGFR 15–29
- Parallel adult rule: loading dose, then 50% of daily dose (label).
- eGFR <15 (not on dialysis)
- Parallel adult rule: loading dose, then 50% of daily dose (label).
- Hemodialysis (intermittent)
- Parallel adult rule: full dose after each hemodialysis (label says pediatric reduction should parallel adults; not studied).
- Peritoneal dialysis
- No data. Specialist input.
- CRRT
- No pediatric CRRT data in the cited sources. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Impaired Renal Function: Fluconazole is cleared primarily by renal excretion as unchanged drug. There is no need to adjust single dose therapy for vaginal candidiasis because of impaired renal function. In patients with impaired renal function who will receive multiple doses of DIFLUCAN, an initial loading dose of 50 mg to 400 mg should be given.
After the loading dose, the daily dose (according to indication) should be based on the following summary: Creatinine Clearance (mL/min) Recommended Dose (%) >50 100 ≤50 (no dialysis) 50 Hemodialysis 100% after each hemodialysis Patients on hemodialysis should receive 100% of the recommended dose after each hemodialysis; on non-dialysis days, patients should receive a reduced dose according to their creatinine clearance. These are suggested dose adjustments based on pharmacokinetics following administration of multiple doses.
Further adjustment may be needed depending upon clinical condition. When serum creatinine is the only measure of renal function available, the following formula (based on sex, weight, and age of the patient) should be used to estimate the creatinine clearance in adults: Males: Weight (kg) × (140 – age) 72 × serum creatinine (mg/100 mL) Females: 0.85 × above value Although the pharmacokinetics of fluconazole has not been studied in pediatric patients with renal insufficiency, dosage reduction in pediatric patients with renal insufficiency should parallel that recommended for adults.
The following formula may be used to estimate creatinine clearance in pediatric patients: K × linear length or height (cm) serum creatinine (mg/100 mL) (Where K=0.55 for pediatric patients older than 1 year and 0.45 for infants.) Administration DIFLUCAN is administered orally. DIFLUCAN can be taken with or without food.
Directions for Mixing the Oral Suspension Prepare a suspension at time of dispensing as follows: tap bottle until all the powder flows freely. To reconstitute, add 24 mL of distilled water or Purified Water (USP) to fluconazole bottle and shake vigorously to suspend powder. Each bottle will deliver 35 mL of suspension. The concentrations of the reconstituted suspensions are as follows: Fluconazole Content per Bottle Concentration of Reconstituted Suspension 350 mg 10 mg/mL 1400 mg 40 mg/mL Note: Shake oral suspension well before using.
Store reconstituted suspension between 30°C (86°F) and 5°C (41°F) and discard unused portion after 2 weeks. Protect from freezing.
Dosing: Pediatric
- Approved ages
- 6 months and older for oropharyngeal and esophageal candidiasis and cryptococcal meningitis; systemic Candida dosing from birth (label).
- Usual dose
- Oropharyngeal or esophageal candidiasis: 6 mg/kg day 1, then 3 mg/kg daily (up to 12 mg/kg/day for esophageal). Systemic Candida, 3 months and older: 25 mg/kg day 1 (maximum 800 mg), then 12 mg/kg daily (maximum 400 mg). Cryptococcal meningitis: 12 mg/kg day 1, then 6 to 12 mg/kg daily (label).
- Maximum dose
- 12 mg/kg/day; systemic Candida maximum 800 mg loading and 400 mg daily.
- Neonates
- Birth to 3 months, gestational age 30 weeks or more: 25 mg/kg day 1, then 12 mg/kg daily; under 30 weeks: 25 mg/kg day 1, then 9 mg/kg daily (systemic Candida; label Table 6).
Label pediatric CrCl formula: K × height (cm) / serum creatinine (mg/dL); K = 0.55 for children over 1 year, 0.45 for infants.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use Use in Pediatric Patients for the Treatment of Oropharyngeal Candidiasis An open-label, randomized, controlled trial has shown DIFLUCAN to be effective in the treatment of oropharyngeal candidiasis in pediatric patients 6 months to 13 years of age. (See CLINICAL STUDIES.) Use in Pediatric Patients for the Treatment of Candida Esophagitis, Systemic Candida Infections, or Cryptococcal Meningitis: The use of DIFLUCAN in pediatric patients with cryptococcal meningitis, Canida esophagitis, or systemic Candida infections is supported by the efficacy shown for these indications in adults and by the results from several small noncomparative pediatric clinical studies.
In addition, pharmacokinetic studies in pediatric patients (See CLINICAL PHARMACOLOGY) have established a dose proportionality between pediatric patients and adults. (See DOSAGE AND ADMINISTRATION.) In a noncomparative study of DIFLUCAN administered to pediatric patients (from birth to less than 17 years) with serious systemic fungal infections, most of which were candidemia, the effectiveness of DIFLUCAN was similar to that reported for the treatment of candidemia in adults.
Of 17 subjects with culture-confirmed candidemia, 11 of 14 (79%) with baseline symptoms (3 were asymptomatic) had a clinical cure; 13/15 (87%) of evaluable patients had a mycologic cure at the end of treatment but two of these patients relapsed at 10 and 18 days, respectively, following cessation of therapy. The efficacy of DIFLUCAN for the suppression of cryptococcal meningitis was successful in 4 of 5 pediatric patients (4 years to 10 years of age) treated in a compassionate-use study of fluconazole for the treatment of life‑threatening or serious mycosis.
There are limited clinical data to support the efficacy of DIFLUCAN for the primary treatment of cryptococcal meningitis in pediatric patients. The safety profile of DIFLUCAN has been studied in 577 pediatric patients from 1 day to 17 years of age who received doses ranging from 1 to 15 mg/kg/day for 1 to 1,616 days. (See ADVERSE REACTIONS.) Use in Pediatric Patients on Extracorporeal Membrane Oxygenation (ECMO) A prospective, open-label, single-center study was conducted to determine the PK and safety of fluconazole in pediatric patients (ages: from birth to 17 years of age) on ECMO (see CLINICAL PHARMACOLOGY).
A loading dose of 35-mg/kg is recommended in pediatric patients on ECMO due to increased volume of distribution (see DOSAGE AND ADMINISTRATION). Use in Prophylaxis of Invasive Candida Infections in Pediatric Patients (premature infants weighing less than 750 grams at birth) Safety and effectiveness of DIFLUCAN for the prophylaxis of invasive candidiasis in pediatric patients (premature infants weighing less than 750 grams at birth) have not been established.
A prospective, randomized, double-blind, placebo-controlled, multicenter trial was conducted in premature infants weighing less than 750 grams at birth to evaluate the efficacy and safety of prophylactic DIFLUCAN 6-mg/kg administered twice weekly for 6 weeks versus placebo (NCT00734539). Efficacy was assessed using the endpoint of death or candidiasis by study day 49.
The results are summarized in Table 4. Table 4: Death or Candidiasis by Day 49 in Premature Infants Receiving DIFLUCAN Prophylaxis DIFLUCAN (N=188) n (%) Placebo (N=173) n (%) P-value Difference (95% CI) Death or candidiasis* 33 (17.6) 38 (22.0) 0.2954 -4.4(-12.6, 3.8) Components of endpoint** Death Candidiasis Missing 27 (14.4) 6 (3.2) 2 (1.0) 25 (14.5) 16 (9.2) 1 (0.5) * Subjects with missing data are imputed as having candidiasis or died. **Subjects may be counted more than once as two fluconazole subjects and four placebo subjects diagnosed with candidiasis subsequently died by day 49.
The most common fatal serious adverse reactions in the DIFLUCAN vs placebo arms, respectively, were necrotizing enterocolitis (NEC), 9 (5%) vs 9 (5%); neonatal bacterial sepsis, 6 (3%) vs 7 (4%); and neonatal respiratory failure, 4 (2%) vs 2 (0.6%). The most common serious adverse reactions (>5%), reported in patients receiving DIFLUCAN prophylaxis are displayed in Table 5.
Table 5. Serious Adverse Reactions* Occurring in >5% of Infants Receiving DIFLUCAN Prophylaxis Adverse Reaction DIFLUCAN (N=188) n(%) Placebo (N=173) n (%) Necrotizing Enterocolitis (NEC) 27 (14) 28 (16) Intestinal Perforation (includes ileal/small intestinal perforation) 13 (7) 7 (4) Neonatal Respiratory Arrest/Neonatal Respiratory Failure 13 (7) 4 (2) Bacterial Sepsis, Neonatal 10 (5) 12 (7) *All serious adverse reactions were assessed and recorded up through 30 days after the final dose of study drug.
Serious adverse reactions included both fatal and non-fatal outcomes.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use In non-AIDS patients, side effects possibly related to fluconazole treatment were reported in fewer patients aged 65 and older (9%, n =339) than for younger patients (14%, n=2240). However, there was no consistent difference between the older and younger patients with respect to individual side effects. Of the most frequently reported (>1%) side effects, rash, vomiting, and diarrhea occurred in greater proportions of older patients.
Similar proportions of older patients (2.4%) and younger patients (1.5%) discontinued fluconazole therapy because of side effects. In post-marketing experience, spontaneous reports of anemia and acute renal failure were more frequent among patients 65 years of age or older than in those between 12 and 65 years of age. Because of the voluntary nature of the reports and the natural increase in the incidence of anemia and renal failure in the elderly, it is however not possible to establish a causal relationship to drug exposure.
Controlled clinical trials of fluconazole did not include sufficient numbers of patients aged 65 and older to evaluate whether they respond differently from younger patients in each indication. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Fluconazole is primarily cleared by renal excretion as unchanged drug.
Because elderly patients are more likely to have decreased renal function, care should be taken to adjust dose based on creatinine clearance. It may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION.)
Dosage forms
Philippines
- Capsule: 50 mg, 150 mg, 200 mg
- Tablet: 50 mg, 150 mg, 200 mg
- ) solution for iv infusion: 2 mg/mL (200 mg/100 mL, 200 mg/100 mL (2 mg/mL
- ) solution for intravenous infusion: 2 mg/mL (100 mg/50 mL, 200 mg/100 mL, and 400 mg/200 mL, 2 mg/mL (200 mg/100 mL, 200 mg in 100 mL (2 mg/mL
- ) solution for i.v. infusion: 2 mg/mL (100 mg/50 mL and 200 mg/100 mL, 2 mg/mL (200 mg/100 mL, 200 mg/100 mL (2 mg/mL
- Solution for iv infusion: 2 mg/mL
- ) solution for injection: 2 mg/mL (200 mg/100 mL
- Film-coated tablet: 200 mg
- Gel: 5 mg/g
- Ophthalmic solution: 3 mg/mL
and 2 more forms; see the products table.
Registered products in the Philippines
78 products registered with the Food and Drug Administration (FDA) Philippines list Fluconazole as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products78
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AmflukonzFluconazole | 150 mg CapsuleAlu/Alu Blister Pack x 1's (Box of 1's), x 6's (Box of 12's) and 10's (Box of 10's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12214-01 | Aug 12, 2027 | |
AploxolFluconazole | 150 mg CapsuleAlu-Clear PVC Blister Pack x 10's (Box of 30's, 50's & 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.,Philippines | — | DRP-15892 | Sep 26, 2029 | |
AploxolFluconazole | 200 mg CapsuleAlu-Clear PVC Blister Pack x 10's (Box of 30's, 50's & 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.,Philippines | — | DRP-15954 | Oct 3, 2029 | |
Axa-Zole FFluconazole | 2mg/mL (200 mg/100 mL) Solution for Intravenous InfusionLDPE Bottle with Cap x 100 mL (Box of 1's) | Rx | Axa Parenterals LimitedIndia | SMHP Pharmaceuticals Incorporated | DR-XY47873 | Mar 30, 2027 | |
Axa-Zole FFluconazole | 2mg/mL (200mg/100mL) Solution for Intravenous InfusionLDPE Bottle with Cap x 100mL (Box of 1's) | Rx | Axa Parenterals LimitedIndia | S.M.H.P. Marketing & Consultancy | DRP-12089 | Mar 30, 2027 | |
BellazoleFluconazole | 150 mg TabletAlu/Clear PVC blister pack x 1’s Box of 1’s | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Bellus Life Solutions, Inc.Importer: Aglobal Care, Inc.Trader: PPJ Pharma Pvt. Ltd. | DRP-8418-01 | Jun 5, 2027 | |
BestflucanFluconazole | 150 mg CapsuleAlu / Clear PVC Blister Pack x 1's (Box of 1's and 5's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Best Remedy Medicines Pharmaceutical Co.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-16902-01 | Sep 9, 2028 | |
CandiclerFluconazole | 200 mg CapsuleAlu/PVC Blister Pack in monocarton x 1's (Box of 10's) | Rx | Magbro Healthcare Pvt. Ltd.India | NAB Trading Corp.Importer: Pharmakon Biotec Inc. | DRP-14150-04 | Jun 30, 2028 | |
ClonazolFluconazole | 2mg/mL (200mg/100mL) Solution for Injection (IV Infusion) | Rx | Eurolife Healthcare Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP17731 | Feb 24, 2031 | |
Desfluzole 200Fluconazole | 200 mg CapsuleAlu-PVC Blister Pack x 4's (Box of 40's) | Rx | Lincoln Pharmaceuticals Ltd.India | Despina Pharma Inc. | DRP-15155 | May 15, 2029 | |
DifluFluconazole | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)5 mL White Opaque LDPE Plastic Dropper Bottle (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | Importer: Sahar International Trading, Inc. | DR-XY45132 | Feb 23, 2031 | |
Diflu-150Fluconazole | 150 mg CapsuleAlu/Alu Blister Pack x 6's (Box of 12's) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading Inc. | DR-XY41571 | Dec 3, 2028 | |
DiflucanFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1’s (Box of 10’s) | Rx | Fareva AmboiseFrance | Importer: Pfizer, Inc. | DRP-1964 | Nov 4, 2031 | |
DiflucanFluconazole | 2 mg/mL Solution For Injection (I.V.)Type I glass vial with red chlorobutyl rubber stopper and aluminium flip-off cap x 100 mL | Rx | Fareva AmboiseFrance | Importer: Pfizer, Inc. | DRP-1962 | Nov 4, 2031 | |
DiflucanFluconazole | 200 mg CapsuleAlu/Clear PVC Blister Pack x 7’s (Box of 28’s) Alu/Clear PVC Blister Pack of 7’s (Box of 28’s) For DOH Use Only | Rx | Fareva AmboiseFrance | Importer: Pfizer, Inc. | DRP-1963 | Nov 4, 2031 | |
DiflucanFluconazole | 50 mg CapsuleAlu/Clear PVC Blister Pack x 7’s (Box of 28’s) | Rx | Fareva AmboiseFrance | Importer: Pfizer, Inc. | DRP-1965 | Nov 4, 2031 | |
DifluseFluconazole | 2 mg/mL (200 mg/100 mL) Solution for IV InfusionUSP Type I Clear glass infusion bottle with chlorobutyl rubber stopper and aluminum cap x 100 mL (Box of 1's) | Rx | Pt. Ferron Par PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc.Trader: PT Dexa Medica | DRP-13871 | May 9, 2028 | |
DifluvidFluconazole | 150 mg CapsuleAlu/PVC Blister pack x 4's (Box of 4's) | Rx | Hovid Bhd.Malaysia | Hovid, Inc. | DR-XY44614 | Jun 8, 2030 | |
FarazoleFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1 per box; Alu/Clear PVC Blister Pack x 1’s per box x 20’s (Box of 20’s) | Rx | Bal Pharma LimitedIndia | Pharmakon Biotec Inc. | DRP-4335 | Mar 27, 2028 | |
FleozolFluconazole | 150 mg CapsuleAlu/PVC Blister Pack x 1's (Box of 10's); Alu/PVC Blister Pack x 10's (Box of 10's and 100's) | Rx | Zee LaboratoriesIndia | Importer: Eon Pharmatek Inc. | DR-XY34485 | Apr 16, 2028 | |
FleozolFluconazole | 200 mg Film-Coated TabletAlu/PVC Blister Pack x 1's (Box of 1's, 10's and 100's); Alu/PVC Blister Pack x 10's (Box of 10's and 100's) | Rx | Helviina Pharmaceuticals Pvt. Ltd.India | Eon Pharmatek, Inc. | DR-XY45498 | Jul 8, 2031 | |
Flona-MFluconazole | 200 mg CapsuleAlu/PVC Blister Pack in monocarton x 1's (Box of 10's) | Rx | Magbro Healthcare Pvt. Ltd.India | Madecs Pharma CorporationImporter: Pharmakon Biotec Inc. | DRP-14150-03 | Jun 30, 2028 | |
FlucazolFluconazole | 2mg/mL (200mg/100mL) Solution for IV InfusionType I Clear Glass Bottle x 100mL (Box of 1's) | Rx | Lu'an Worldbest Pharmaceutical Co., Ltd.China | Global Pharmatrade | DR-XY41386 | Nov 21, 2027 | |
FlucodrazFluconazole | 200 mg TabletAlu/PVDC Blister Pack x 4's (Box of 4's) | Rx | The Madras PharmaceuticalsIndia | Aglobal Care Inc. | DRP-15950 | Oct 3, 2029 | |
FlucofarmFluconazole | 2 mg/mL Solution for IV InfusionLDPE FFS Bottle x 100 mL (Box of 1's) | Rx | Amanta Healthcare Ltd.India | Uni-Pharma Phils., Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4787-01 | Oct 4, 2028 | |
FlucogeFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1 per box; Alu/Clear PVC Blister Pack x 1’s per box x 20’s (Box of 20's) | Rx | Bal Pharma LimitedIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-4335-06 | Mar 27, 2028 | |
FlucolifeFluconazole | 200 mg/100 mL (2 mg/mL) Solution for I.V. InfusionLDPE Blow Molded Plastic Bottle x 100mL (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-7923 | May 9, 2031 | |
FluconFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1's (Box of 1's) | Rx | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-2045-03 | Mar 23, 2030 | |
FluconasaphFluconazole | 200 mg CapsuleAlu/Alu Blister Pack x 1's (Box of 1's) Alu/Alu Blister Pack x 6's (Box of 12's) Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-15999 | Jan 23, 2032 | |
FluconasaphFluconazole | 200mg/100ml (2mg/mL) Solution For IV Infusion100 mL White LDPE Plastic Bottle (Box of 1's) | Rx | Althea Pharma Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-12961 | Nov 10, 2027 | |
FluconazFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1's (Box of 1's) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-2045 | Mar 23, 2030 | |
FluconobasFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1's (Box of 1's) | Rx | FRIENDS PHARMA (PVT.) LTD.Pakistan | RAQUEL-ABBAS PHARMACEUTICALS & GENERAL MERCHANDISE | DR-XY42609 | Sep 9, 2028 | |
FluconobasFluconazole | 150 mg CapsuleAlu / Clear PVC Blister Pack x 1's (Box of 1's and 5's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-16902 | Sep 9, 2028 | |
FluconobasFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1's (Box of 1's); Alu/Clear PVC Blister Pack x 5's (Box of 5's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-17247 | Sep 9, 2028 | |
FlucopharmFluconazole | 2 mg/mL (100 mg/50 mL and 200 mg/100 mL) Solution for I.V. InfusionUSP Type I Colorless Glass Bottle x 50 mL (Box of 1's); USP Type II Colorless Glass Bottle x 100 mL (Box of 1's) | Rx | Limited Liability Company "Yuria Pharm"18030 | Uni-Pharma Phils., Inc.Importer: Ambicare Pharmaceuticals Inc. | DR-XY45756 | Jan 24, 2032 | |
FlucoralFluconazole | 200 mg CapsuleAlu/Clear PVC-PVdC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DR-XY46552 (For DOH Only) | Apr 15, 2029 | |
FluczanFluconazole | 200mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 50's) | Rx | Siam Bheasach Co., Ltd.Thailand | Endure Medical, Inc. | DR-XY48762 | Jun 6, 2028 | |
FlukalFluconazole | 200mg in 100mL (2mg/mL) Solution for Intravenous InfusionPP Bottle with Cap x 100 mL | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DR-XY47872 | Mar 30, 2027 | |
FluonazoleFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1's (Box of 1's) | Rx | XL Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-2045-02 | Mar 23, 2030 | |
Fluoral-200Fluconazole | 200 mg TabletAlu/PVC Blister Pack x 4's (Box of 20's) | Rx | The Madras PharmaceuticalIndia | Uni-Pharma Phils., Inc.Importer: Aglobal Care Inc. | DRP-15950-01 | Oct 3, 2029 | |
Flusum®Fluconazole | 5 mg/g (0.5% w/w) GelLami Tube x 30 g (Box of 1's) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DR-XY45859 | Apr 26, 2027 | |
FluxFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1 per box (Box of 1's); Alu/Clear PVC Blister Pack x 1’s per box x 20’s (Box of 20’s) | Rx | Bal Pharma Ltd.India | Teramedix Pharma Trading Inc.Importer: PHARMAKON BIOTEC INC. | DRP-4335-02 | Mar 27, 2028 | |
FluxarFluconazole | 2 mg/mL (200 mg/100 mL) Solution for IV InfusionType I Clear Glass Bottle in 100mL (net content) Box of 1's | Rx | PT. Novell Pharmaceutical LaboratoriesBogor 16962 Indonesia | Prosweal Healthcare Inc. | DR-XY45545 | Aug 5, 2031 | |
FluzelFluconazole | 200 mg CapsuleAlu/PVC Blister Pack in monocarton x 1's (Box of 10' s) | Rx | MAGBRO HEALTHCARE PVT. LTD.India | Pharmakon Biotec Inc. | DRP-14150 | Jun 30, 2028 | |
Fluzole-150Fluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1 per box; Alu/Clear PVC Blister Pack x 1’s per box x 20’s (Box of 20’s) | Rx | Bal Pharma LimitedIndia | Labmate Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-4335-03 | Mar 27, 2028 | |
FucozoleFluconazole | 150 mg CapsuleAlu/PVC Blister Pack x 1's (Box of 1's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Vape Distribution and DrugstoreImporter: Yung Shin (Philippines), Inc. | DRP-9969-01 | Feb 3, 2027 | |
FukoleFluconazole | 150 mg CapsuleAlu/PVC Blister Pack x 1's (Box of 1's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DRP-9969 | Feb 3, 2027 | |
FungbyFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1's (Box of 1's) | Rx | XL Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-2045-01 | Mar 23, 2030 | |
FungicanFluconazole | 2 mg/mL (200 mg/100 mL) Solution for I.V. InfusionLDPE Bottle with Plastic Cap x 100 mL Box of 1's | Rx | Amanta Healthcare Ltd.India | Endure Medical, Inc. | DR-XY35400 | Feb 4, 2029 | |
FungiconFluconazole | 150 mg CapsuleBlister Pack x 1's (Box of 25's) | Rx | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DRP-15168 | Oct 24, 2031 | |
Fungillen-B150Fluconazole | 150mg CapsuleAlu/PVC Blister Pack x 10’s (Box of 30’s and 100’s) | Rx | Belco PharmIndia | Ollen Pharm Trading Inc. | DRP-19079 | Oct 28, 2031 | |
Fungillen-B200Fluconazole | 200 mg CapsuleAlu/PVC Blister Pack x 10’s (Box of 30’s and 100’s) | Rx | Belco PharmIndia | Ollen Pharm Trading Inc. | DRP-19080 | Oct 28, 2031 | |
Funginil I.V.Fluconazole | 2 mg/mL Solution for IV InfusionLDPE FFS Bottle x 100 mL Box of 1's | Rx | Amanta Healthcare Ltd.India | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4787 | Oct 4, 2028 | |
FungisaphFluconazole | 2 mg/mL (200 mg/100 mL) Solution for IV Infusion100 mL White LDPE Plastic Bottle (Box of 1's) | Rx | Jedux Parenteral Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifescience PVT. Ltd. | DRP-13041 | Nov 22, 2027 | |
FungivFluconazole | 2mg/mL (200 mg/100 mL) Solution for I.V. Infusion100 mL LDPE Poly Bottle with plastic dust cap Box of 1's | Rx | Amanta Healthcare Ltd.India | Biocare Lifesciences, Inc. | DRP-7457 | Nov 8, 2027 | |
Fungiv TabFluconazole | 200 mg CapsuleAlu/PVC Blister Pack in monocarton x 1's (Box of 10's) | Rx | Magbro Healthcare Pvt. Ltd.India | Biocare Lifesciences, Inc.Importer: Pharmakon Biotec Inc. | DRP-14150-02 | Jun 30, 2028 | |
FungsoftFluconazole | 150 mg Vaginal Soft Gelatin CapsuleAlu/PVC Blister Pack x 1's (Box of 7's) | Rx | Gelnova Laboratories (India) Private LimitedIndia | SRS Life Sciences Inc. | DR-XY42312 | Jul 25, 2028 | |
FunzelaFluconazole | 150 mg TabletAlu/PVC Blister Pack x 1's (Box of 1's); Alu/PVC Blister Pack x 1's (Box of 1's) in a tertiary packaging in 10's | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY29105 | Dec 21, 2027 | |
FunzelaFluconazole | 200 mg TabletAlu/PVC Blister Pack of 10's (Box of 20's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY32179 | Dec 21, 2027 | |
FunzelaFluconazole | 50 mg TabletAlu/PVC Blister Pack of 10's (Box of 20's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY32618 | Nov 5, 2027 | |
Glonaz 150Fluconazole | 150 mg TabletAlu/Clear PVC Blister Pack x 1’s (Box of 1’s) | Rx | AKRITI PHARMACEUTICALS PVT. LTD.India | AGLOBAL CARE, INC.Trader: PPJ PHARMA PVT. LTD. | DRP-8418 | Jun 5, 2027 | |
MedofluconFluconazole | 150 mg CapsulePVC/Alu Blister Pack x 1's (Box of 1 capsule) | Rx | Medochemie Ltd. (Central Factory) | Britton Distributions, Inc. | DR-XY45744 | Nov 5, 2031 | |
MedofluconFluconazole | 50 mg CapsuleAlu / PVC blister pack x 7's (Box of 7's) | Rx | MEDOCHEMIE LTD. (Central Factory)Cyprus | BRITTON DISTRIBUTIONS, INC. | DR-XY42830 | Oct 17, 2028 | |
MycozoleFluconazole | 150 mg CapsuleAlu-PVC Blister Pack x 10's (Box of 20's) (Box of 20's) | Rx | Swisspharma Research Laboratories Inc.Philippines | The Cathay Drug Co., Inc. | DR-XY38100 | Jun 15, 2030 | |
MycozoleFluconazole | 2 mg/mL (200 mg/100 mL) Solution for Intravenous InfusionType II clear and colorless glass vial with chlorobutyl rubber stopper x 100 mL (net content), aluminum seal and blue flip-off cap (Box of 1's) | Rx | Taiwan Biotech Co., Ltd.Taiwan | The Cathay Drug Co., Inc. | DRP-15214 | May 29, 2029 | |
MycozoleFluconazole | 50 mg CapsuleAlu-PVC Blister Pack x 10's (Box of 20's) | Rx | Swiss Pharma Research Laboratories, Inc.Philippines | The Cathay Drug Company, Inc. | DR-XY38101 | Jun 15, 2030 | |
Mycozole IVFluconazole | 2 mg/ mL (200 mg/ 100 mL) Solution for IV Infusion100 mL LDPE Poly Bottle with plastic dust cap (Box of 1's) | Rx | AMANTA HEALTHCARE LTD.India | THE CATHAY DRUG CO., INC.Importer: BIOCARE LIFESCIENCES, INC. | DRP-7457-01 | Nov 8, 2027 | |
RazoleFluconazole | 150 mg CapsuleAlu-Clear PVC Blister Pack x 10's (Box of 30's, 50's & 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-15892-02 | Sep 26, 2029 | |
RazoleFluconazole | 200 mg CapsuleAlu-Clear PVC Blister Pack x 10's (Box of 30's, 50's & 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-15954-01 | Oct 3, 2029 | |
RetaconFluconazole | 150 mg TabletAlu/Clear PVC Blister Pack x 1’s (Box of 1’s) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Reta DrugImporter: Aglobal Care, Inc. | DRP-8418-2 | Jun 5, 2027 | |
SaphcozoleFluconazole | 50 mg CapsuleAlu/Alu Blister Pack x 1's (Box of 1's), 6's (Box of 12's), and 10's (Box of 30's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17142 | Oct 7, 2030 | |
SaphlucazFluconazole | 150 mg CapsuleAlu/Alu Blister Pack x 1's (Box of 1's) Alu/Alu Blister Pack x 6's (Box of 12's) Alu/Alu Blister Pack x 10's (Box of 10's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-12214 | Mar 30, 2032 | |
TerizoleFluconazole | 200 mg CapsuleAlu/PVC Blister Pack x 1' per box x 10's (Box of 10's) | Rx | MAGBRO HEALTHCARE PVT. LTD.India | TERAMEDIX PHARMA TRADING INC. | DRP-14151 | Jun 30, 2028 | |
ZiludexFluconazole | 150 mg CapsuleAlu/Clear PVC Blister Pack x 1’s per box x 20’s (Box of 20’s) | Rx | Bal Pharma Limited (Unit-I)India | Zeldix Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-4335-07 | Mar 27, 2028 | |
Ziludex-200Fluconazole | 200 mg CapsuleAlu/ PVC Blister Pack in monocarton x 1's (Box of 10's) | Rx | Magbro Healthcare Pvt. Ltd.India | Zeldix Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-14150-01 | Jun 30, 2028 | |
ZolegenFluconazole | 150 mg CapsuleAlu-Clear PVC Blister Pack x 10's (Box of 30's, 50's & 100's) | Rx | Azarias Pharmaceutical Laboratries Inc.Philippines | Eba Generisch Trading Inc. | DRP-15892-01 | Sep 26, 2029 | |
ZolegenFluconazole | 200 mg CapsuleAlu-Clear PVC Blister Pack x 10's (Box of 30's, 50's & 100's) | Rx | Azarias Pharmaceutical Laboratries Inc.Philippines | Eba Generisch Trading Inc. | DRP-15954-02 | Oct 3, 2029 | |
(no brand name)Fluconazole | 2 mg/mL (100 mg/50 mL, 200 mg/100 mL, and 400 mg/200 mL) Solution for Intravenous InfusionLDPE Plastic (Ecoflac Plus) Bottle x 50 mL, 100 mL, 200 mL | Rx | B. Braun Medical, SASpain | Importer: B. Braun Medical Supplies, Incorporated | DR-XY47565 | Nov 29, 2026 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS (1) Hepatic injury: DIFLUCAN should be administered with caution to patients with liver dysfunction. DIFLUCAN has been associated with rare cases of serious hepatic toxicity, including fatalities primarily in patients with serious underlying medical conditions. In cases of DIFLUCAN-associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex, or age of the patient has been observed.
DIFLUCAN hepatotoxicity has usually, but not always, been reversible on discontinuation of therapy. Patients who develop abnormal liver function tests during DIFLUCAN therapy should be monitored for the development of more severe hepatic injury. DIFLUCAN should be discontinued if clinical signs and symptoms consistent with liver disease develop that may be attributable to DIFLUCAN.
(2) Anaphylaxis: In rare cases, anaphylaxis has been reported. (3) Dermatologic: Exfoliative skin disorders during treatment with DIFLUCAN have been reported. Fatal outcomes have been reported in patients with serious underlying diseases. Patients with deep seated fungal infections who develop rashes during treatment with DIFLUCAN should be monitored closely and the drug discontinued if lesions progress.
Fluconazole should be discontinued in patients treated for superficial fungal infection who develop a rash that may be attributed to fluconazole. (4) Potential for fetal harm: There are no adequate and well-controlled clinical trials of DIFLUCAN in pregnant women. Case reports describe a pattern of distinct congenital anomalies in infants exposed in utero to high dose maternal fluconazole (400 to 800 mg/day) during most or all of the first trimester.
These reported anomalies are similar to those seen in animal studies. If DIFLUCAN is used during pregnancy or if the patient becomes pregnant while taking the drug, the patient should be informed of the potential hazard to the fetus. Effective contraceptive measures should be considered in women of child-bearing potential who are being treated with DIFLUCAN 400 to 800 mg/day and should continue throughout the treatment period and for approximately 1 week (5 to 6 half-lives) after the final dose.
Epidemiological studies suggest a potential risk of spontaneous abortion and congenital abnormalities in infants whose mothers were treated with 150 mg of fluconazole as a single or repeated dose in the first trimester, but these epidemiological studies have limitations and these findings have not been confirmed in controlled clinical trials. (See PRECAUTIONS: Pregnancy.)
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| QT-prolonging CYP3A4 substrates (erythromycin, pimozide, quinidine) | Avoid | QT prolongation, torsades (label). | Contraindicated. |
| Tacrolimus, cyclosporine, sirolimus | Adjust or monitor | Higher immunosuppressant levels; nephrotoxicity (label). | Monitor levels; reduce dose. |
| Warfarin, phenytoin, sulfonylureas | Adjust or monitor | Higher levels: bleeding, toxicity, hypoglycemia (label). | Monitor INR, levels, glucose. |
| Hydrochlorothiazide | Minor | Raises fluconazole levels about 40% (label). | Usually no action. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
Drug Interactions: (See CONTRAINDICATIONS.) Fluconazole is a moderate CYP2C9 and CYP3A4 inhibitor. Fluconazole is also a strong inhibitor of CYP2C19. Patients treated with DIFLUCAN, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.
In addition to the observed /documented interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolized by CYP2C9, CYP2C19, and CYP3A4 coadministered with fluconazole. Therefore, caution should be exercised when using these combinations and the patients should be carefully monitored.
The enzyme inhibiting effect of fluconazole persists 4 to 5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole. Clinically or potentially significant drug interactions between DIFLUCAN and the following agents/classes have been observed and are described in greater detail below: Abrocitinib: Drug interaction studies indicate that when coadministered with fluconazole (strong inhibitor of CYP2C19; moderate inhibitor of CYP2C9 and CYP3A4), the systemic exposure of abrocitinib and its active metabolites increased (See CLINICAL PHARMACOLOGY).
Avoid concomitant use of abrocitinib with DIFLUCAN. Refer to the abrocitinib Prescribing Information for additional details. Alfentanil: A study observed a reduction in clearance and distribution volume as well as prolongation of t ½ of alfentanil following concomitant treatment with fluconazole. A possible mechanism of action is fluconazole's inhibition of CYP3A4.
Dosage adjustment of alfentanil may be necessary. Amiodarone: Concomitant administration of fluconazole with amiodarone may increase QT prolongation. Caution must be exercised if the concomitant use of fluconazole and amiodarone is necessary, notably with high-dose fluconazole (800 mg). Amitriptyline, nortriptyline: Fluconazole increases the effect of amitriptyline and nortriptyline. 5-Nortriptyline and/or S-amitriptyline may be measured at initiation of the combination therapy and after 1 week.
Dosage of amitriptyline/nortriptyline should be adjusted, if necessary. Amphotericin B: Concurrent administration of fluconazole and amphotericin B in infected normal and immunosuppressed mice showed the following results: a small additive antifungal effect in systemic infection with Candida albicans, no interaction in intracranial infection with Cryptococcus neoformans, and antagonism of the two drugs in systemic infection with A. fumigatus.
The clinical significance of results obtained in these studies is unknown. Azithromycin: An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 1200 mg oral dose of azithromycin on the pharmacokinetics of a single 800 mg oral dose of fluconazole as well as the effects of fluconazole on the pharmacokinetics of azithromycin.
There was no significant pharmacokinetic interaction between fluconazole and azithromycin. Calcium channel blockers: Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil, and felodipine) are metabolized by CYP3A4. Fluconazole has the potential to increase the systemic exposure of the calcium channel antagonists.
Frequent monitoring for adverse events is recommended. Carbamazepine: Fluconazole inhibits the metabolism of carbamazepine and an increase in serum carbamazepine of 30% has been observed. There is a risk of developing carbamazepine toxicity. Dosage adjustment of carbamazepine may be necessary depending on concentration measurements/effect.
Celecoxib: During concomitant treatment with fluconazole (200 mg daily) and celecoxib (200 mg), the celecoxib C max and AUC increased by 68% and 134%, respectively. Half of the celecoxib dose may be necessary when combined with fluconazole. Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants.
In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended.
Dose adjustment of warfarin may be necessary. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Cyclophosphamide: Combination therapy with cyclophosphamide and fluconazole results in an increase in serum bilirubin and serum creatinine. The combination may be used while taking increased consideration to the risk of increased serum bilirubin and serum creatinine.
Cyclosporine: DIFLUCAN significantly increases cyclosporine levels in renal transplant patients with or without renal impairment. Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) This combination may be used by reducing the dosage of cyclosporine depending on cyclosporine concentration.
Fentanyl: One fatal case of possible fentanyl-fluconazole interaction was reported. The author judged that the patient died from fentanyl intoxication. Furthermore, in a randomized crossover study with 12 healthy volunteers, it was shown that fluconazole delayed the elimination of fentanyl significantly. Elevated fentanyl concentration may lead to respiratory depression.
HMG-CoA reductase inhibitors: The risk of myopathy and rhabdomyolysis increases when fluconazole is coadministered with HMG-CoA reductase inhibitors metabolized through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin (decreased hepatic metabolism of the statin). If concomitant therapy is necessary, the patient should be observed for symptoms of myopathy and rhabdomyolysis and creatinine kinase should be monitored.
HMG-CoA reductase inhibitors should be discontinued if a marked increase in creatinine kinase is observed or myopathy/rhabdomyolysis is diagnosed or suspected. Dose reduction of statins may be needed. Refer to the statin-specific prescribing information for details. Hydrochlorothiazide: In a pharmacokinetic interaction study, coadministration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentrations of fluconazole by 40%.
An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. Ibrutinib: Moderate inhibitors of CYP3A4 such as fluconazole may increase plasma ibrutinib concentrations and increase risk of adverse reactions associated with ibrutinib. If ibrutinib and fluconazole are concomitantly administered, reduce the dose of ibrutinib as instructed in ibrutinib prescribing information and the patient should be frequently monitored for any adverse reactions associated with ibrutinib.
Ivacaftor and fixed dose ivacaftor combinations (e.g., tezacaftor/ivacaftor and ivacaftor/tezacaftor/elexacaftor): Coadministration with ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, increased ivacaftor exposure by 3-fold. If used concomitantly with a moderate inhibitor of CYP3A4, such as fluconazole, a reduction in the dose of ivacaftor (or ivacaftor combination) is recommended as instructed in the ivacaftor (or ivacaftor combination) prescribing information.
Lemborexant: Concomitant administration of fluconazole increased lemborexant Cmax and AUC by approximately 1.6- and 4.2-fold, respectively which is expected to increase risk of adverse reactions, such as somnolence. Avoid concomitant use of DIFLUCAN with lemborexant. Losartan: Fluconazole inhibits the metabolism of losartan to its active metabolite (E-31 74) which is responsible for most of the angiotensin Il-receptor antagonism which occurs during treatment with losartan.
Patients should have their blood pressure monitored continuously. Lurasidone: Concomitant use of moderate inhibitors of CYP3A4 such as fluconazole may increase lurasidone plasma concentrations. If concomitant use cannot be avoided, reduce the dose of lurasidone as instructed in the lurasidone prescribing information. Methadone: Fluconazole may enhance the serum concentration of methadone.
Dosage adjustment of methadone may be necessary. Non-steroidal anti-inflammatory drugs: The C max and AUC of flurbiprofen were increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. Similarly, the C max and AUC of the pharmacologically active isomer [S-(+)-ibuprofen] were increased by 15% and 82%, respectively, when fluconazole was coadministered with racemic ibuprofen (400 mg) compared to administration of racemic ibuprofen alone.
Although not specifically studied, fluconazole has the potential to increase the systemic exposure of other non-steroidal anti-inflammatory drugs (NSAIDs) that are metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended.
Adjustment of dosage of NSAIDs may be needed. Olaparib: Moderate inhibitors of CYP3A4 such as fluconazole increase olaparib plasma concentrations; concomitant use is not recommended. If the combination cannot be avoided, reduce the dose of olaparib as instructed in the LYNPARZA ® (Olaparib) Prescribing Information. Oral contraceptives: Two pharmacokinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole.
There were no relevant effects on hormone level in the 50 mg fluconazole study, while at 200 mg daily, the AUCs of ethinyl estradiol and levonorgestrel were increased 40% and 24%, respectively. Thus, multiple-dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of the combined oral contraceptive.
Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.
When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin.
Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Pimozide: Although not studied in vitro or in vivo, concomitant administration of fluconazole with pimozide may result in inhibition of pimozide metabolism. Increased pimozide plasma concentrations can lead to QT prolongation and rare occurrences of torsade de pointes.
Coadministration of fluconazole and pimozide is contraindicated. Prednisone: There was a case report that a liver-transplanted patient treated with prednisone developed acute adrenal cortex insufficiency when a 3 month therapy with fluconazole was discontinued. The discontinuation of fluconazole presumably caused an enhanced CYP3A4 activity which led to increased metabolism of prednisone.
Patients on long-term treatment with fluconazole and prednisone should be carefully monitored for adrenal cortex insufficiency when fluconazole is discontinued. Quinidine: Although not studied in vitro or in vivo, concomitant administration of fluconazole with quinidine may result in inhibition of quinidine metabolism. Use of quinidine has been associated with QT prolongation and rare occurrences of torsade de pointes.
Coadministration of fluconazole and quinidine is contraindicated. (See CONTRAINDICATIONS.) Rifabutin: There have been reports that an interaction exists when fluconazole is administered concomitantly with rifabutin, leading to increased serum levels of rifabutin up to 80%. There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.
Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin.
(See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Saquinavir: Fluconazole increases the AUC of saquinavir by approximately 50%, C max by approximately 55%, and decreases the clearance of saquinavir by approximately 50% due to inhibition of saquinavir's hepatic metabolism by CYP3A4 and inhibition of P-glycoprotein. Dosage adjustment of saquinavir may be necessary.
Short-acting benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously.
If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Sirolimus: Fluconazole increases plasma concentrations of sirolimus presumably by inhibiting the metabolism of sirolimus via CYP3A4 and P-glycoprotein.
This combination may be used with a dosage adjustment of sirolimus depending on the effect/concentration measurements. Tacrolimus: Fluconazole may increase the serum concentrations of orally administered tacrolimus up to 5 times due to inhibition of tacrolimus metabolism through CYP3A4 in the intestines. No significant pharmacokinetic changes have been observed when tacrolimus is given intravenously.
Increased tacrolimus levels have been associated with nephrotoxicity. Dosage of orally administered tacrolimus should be decreased depending on tacrolimus concentration. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Theophylline: DIFLUCAN increases the serum concentrations of theophylline. Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended.
(See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Tofacitinib: Systemic exposure to tofacitinib is increased when tofacitinib is coadministered with fluconazole. Reduce the dose of tofacitinib when given concomitantly with fluconazole (i.e., from 5 mg twice daily to 5 mg once daily as instructed in the XELJANZ ® [tofacitinib] label).
(See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Tolvaptan: Plasma exposure to tolvaptan is significantly increased (200% in AUC; 80% in C max) when tolvaptan, a CYP3A4 substrate, is coadministered with fluconazole, a moderate CYP3A4 inhibitor. This interaction may result in the risk of a significant increase in adverse reactions associated with tolvaptan, particularly significant diuresis, dehydration, and acute renal failure.
If tolvaptan and fluconazole are concomitantly administered, the tolvaptan dose should be reduced as instructed in the tolvaptan prescribing information and the patient should be frequently monitored for any adverse reactions associated with tolvaptan. Triazolam: Fluconazole increases the AUC of triazolam (single dose) by approximately 50%, C max by 20% to 32%, and increases t½ by 25% to 50 % due to the inhibition of metabolism of triazolam.
Dosage adjustments of triazolam may be necessary. Vinca alkaloids: Although not studied, fluconazole may increase the plasma levels of the vinca alkaloids (e.g., vincristine and vinblastine) and lead to neurotoxicity, which is possibly due to an inhibitory effect on CYP3A4. Vitamin A: Based on a case report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, central nervous system (CNS) related undesirable effects have developed in the form of pseudotumor cerebri, which disappeared after discontinuation of fluconazole treatment.
This combination may be used but the incidence of CNS related undesirable effects should be borne in mind. Voriconazole: Avoid concomitant administration of voriconazole and fluconazole. Monitoring for adverse events and toxicity related to voriconazole is recommended; especially, if voriconazole is started within 24 h after the last dose of fluconazole.
(See CLINICAL PHARMACOLOGY: Drug Interaction Studies.) Zidovudine: Fluconazole increases the C max and AUC of zidovudine by 84% and 74%, respectively, due to an approximately 45% decrease in oral zidovudine clearance. The half-life of zidovudine was likewise prolonged by approximately 128% following combination therapy with fluconazole.
Patients receiving this combination should be monitored for the development of zidovudine-related adverse reactions. Dosage reduction of zidovudine may be considered. Physicians should be aware that interaction studies with medications other than those listed in the CLINICAL PHARMACOLOGY section have not been conducted, but such interactions may occur.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Drug Interactions: (See CONTRAINDICATIONS .) Fluconazole is a moderate CYP2C9 and CYP3A4 inhibitor.
Fluconazole is also a strong inhibitor of CYP2C19.
Patients treated with DIFLUCAN, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.
In addition to the observed /documented interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolized by CYP2C9, CYP2C19, and CYP3A4 coadministered with fluconazole.
Clinically or potentially significant drug interactions between DIFLUCAN and the following agents/classes have been observed and are described in greater detail below: Abrocitinib: Drug interaction studies indicate that when coadministered with fluconazole (strong inhibitor of CYP2C19; moderate inhibitor of CYP2C9 and CYP3A4), the systemic exposure of abrocitinib and its active metabolites increased (See CLINICAL PHARMACOLOGY ).
A possible mechanism of action is fluconazole's inhibition of CYP3A4.
Calcium channel blockers: Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil, and felodipine) are metabolized by CYP3A4.
HMG-CoA reductase inhibitors: The risk of myopathy and rhabdomyolysis increases when fluconazole is coadministered with HMG-CoA reductase inhibitors metabolized through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin (decreased hepatic metabolism of the statin).
Adverse reactions
Common
- Headache, nausea, abdominal pain
- Diarrhea, dyspepsia, dizziness, taste change
Serious
- Hepatotoxicity (rarely fatal)
- QT prolongation and torsades de pointes
- Anaphylaxis; exfoliative skin reactions, DRESS
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS DIFLUCAN is generally well tolerated. In some patients, particularly those with serious underlying diseases such as AIDS and cancer, changes in renal and hematological function test results and hepatic abnormalities have been observed during treatment with fluconazole and comparative agents, but the clinical significance and relationship to treatment is uncertain.
In Patients Receiving a Single Dose for Vaginal Candidiasis: During comparative clinical studies conducted in the United States, 448 patients with vaginal candidiasis were treated with DIFLUCAN, 150 mg single dose. The overall incidence of side effects possibly related to DIFLUCAN was 26%. In 422 patients receiving active comparative agents, the incidence was 16%.
The most common treatment-related adverse events reported in the patients who received 150 mg single dose fluconazole for vaginitis were headache (13%), nausea (7%), and abdominal pain (6%). Other side effects reported with an incidence equal to or greater than 1% included diarrhea (3%), dyspepsia (1%), dizziness (1%), and taste perversion (1%).
Most of the reported side effects were mild to moderate in severity. Rarely, angioedema and anaphylactic reaction have been reported in marketing experience. In Patients Receiving Multiple Doses for Other Infections: Sixteen percent of over 4000 patients treated with DIFLUCAN (fluconazole) in clinical trials of 7 days or more experienced adverse events.
Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3% of patients due to laboratory test abnormalities. Clinical adverse events were reported more frequently in HIV infected patients (21%) than in non-HIV infected patients (13%); however, the patterns in HIV infected and non-HIV infected patients were similar.
The proportions of patients discontinuing therapy due to clinical adverse events were similar in the two groups (1.5%). The following treatment-related clinical adverse events occurred at an incidence of 1% or greater in 4048 patients receiving DIFLUCAN for 7 or more days in clinical trials: nausea 3.7%, headache 1.9%, skin rash 1.8%, vomiting 1.7%, abdominal pain 1.7%, and diarrhea 1.5%.
Hepato-biliary: In combined clinical trials and marketing experience, there have been rare cases of serious hepatic reactions during treatment with DIFLUCAN. (See WARNINGS.) The spectrum of these hepatic reactions has ranged from mild transient elevations in transaminases to clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities.
Instances of fatal hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly AIDS or malignancy) and often while taking multiple concomitant medications. Transient hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors.
In each of these cases, liver function returned to baseline on discontinuation of DIFLUCAN. In two comparative trials evaluating the efficacy of DIFLUCAN for the suppression of relapse of cryptococcal meningitis, a statistically significant increase was observed in median AST (SGOT) levels from a baseline value of 30 IU/L to 41 IU/L in one trial and 34 IU/L to 66 IU/L in the other.
The overall rate of serum transaminase elevations of more than 8 times the upper limit of normal was approximately 1% in fluconazole-treated patients in clinical trials. These elevations occurred in patients with severe underlying disease, predominantly AIDS or malignancies, most of whom were receiving multiple concomitant medications, including many known to be hepatotoxic.
The incidence of abnormally elevated serum transaminases was greater in patients taking DIFLUCAN concomitantly with one or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid, or oral sulfonylurea hypoglycemic agents. Post-Marketing Experience In addition, the following adverse events have occurred during post-marketing experience.
Immunologic: In rare cases, anaphylaxis (including angioedema, face edema and pruritus) has been reported. Body as a Whole: Asthenia, fatigue, fever, malaise. Cardiovascular: QT prolongation, torsade de pointes. (See PRECAUTIONS.) Central Nervous System: Seizures, dizziness. Hematopoietic and Lymphatic: Leukopenia, including neutropenia and agranulocytosis, thrombocytopenia.
Metabolic: Hypercholesterolemia, hypertriglyceridemia, hypokalemia. Gastrointestinal: Cholestasis, dry mouth, hepatocellular damage, dyspepsia, vomiting. Other Senses: Taste perversion. Musculoskeletal System: myalgia. Nervous System: Insomnia, paresthesia, somnolence, tremor, vertigo. Skin and Appendages: Acute generalized exanthematous pustulosis, drug eruption including fixed drug eruption, increased sweating, exfoliative skin disorders including Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS) (See WARNINGS), alopecia.
Adverse Reactions in Pediatric Patients: The pattern and incidence of adverse events and laboratory abnormalities recorded during pediatric clinical trials are comparable to those seen in adults. In Phase II/III clinical trials conducted in the United States and in Europe, 577 pediatric patients, ages 1 day to 17 years were treated with DIFLUCAN at doses up to 15 mg/kg/day for up to 1,616 days.
Thirteen percent of pediatric patients experienced treatment-related adverse events. The most commonly reported events were vomiting (5%), abdominal pain (3%), nausea (2%), and diarrhea (2%). Treatment was discontinued in 2.3% of patients due to adverse clinical events and in 1.4% of patients due to laboratory test abnormalities.
The majority of treatment-related laboratory abnormalities were elevations of transaminases or alkaline phosphatase. Percentage of Patients With Treatment-Related Side Effects Fluconazole (N=577) Comparative Agents (N=451) With any side effect 13.0 9.3 Vomiting 5.4 5.1 Abdominal pain 2.8 1.6 Nausea 2.3 1.6 Diarrhea 2.1 2.2 Clinical Trials Experience in Pediatric Patients Safety in Prophylaxis of Invasive Candida Infections in Premature infants weighing less than 750 grams at birth In a Phase 3 clinical trial of pediatric patients (premature infants weighing less than 750 grams at birth), the incidence of intestinal perforation in infants receiving DIFLUCAN prophylaxis was higher compared to infants receiving placebo (see PRECAUTIONS: Pediatric Use).
Safety in Pediatric Patients Receiving ECMO A cohort of 20 pediatric patients (1 day to 17 years of age) on ECMO received DIFLUCAN in a prospective, open-label, single-center safety and PK ECMO study. The adverse reaction profile of DIFLUCAN in these patients was similar to that of adult and pediatric non-ECMO patients (See PRECAUTIONS: Pediatric Use).
Adverse reaction frequency tables (US label) US FDA label
| Fluconazole (N=577) | Comparative Agents (N=451) | |
|---|---|---|
| With any side effect | 13.0 | 9.3 |
| Vomiting | 5.4 | 5.1 |
| Abdominal pain | 2.8 | 1.6 |
| Nausea | 2.3 | 1.6 |
| Diarrhea | 2.1 | 2.2 |
Monitoring parameters
- Kidney function for dose; liver tests; QT interval with other QT-prolonging drugs; potassium and magnesium. Levels of interacting drugs (tacrolimus, cyclosporine, warfarin, phenytoin, sulfonylureas). Kidney
- Kidney function
- Liver tests
- QT and electrolytes when at risk
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects Potential for Fetal Harm: Use in pregnancy should be avoided except in patients with severe or potentially life-threatening fungal infections in whom fluconazole may be used if the anticipated benefit outweighs the possible risk to the fetus. A few published case reports describe a pattern of distinct congenital anomalies in infants exposed in utero to high dose maternal fluconazole (400 to 800 mg/day) during most or all of the first trimester.
These reported anomalies are similar to those seen in animal studies. Effective contraceptive measures should be considered in women of child-bearing potential who are being treated with DIFLUCAN 400 to 800 mg/day and should continue throughout the treatment period and for approximately 1 week (5 to 6 half-lives) after the final dose.
If DIFLUCAN is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be informed of the potential hazard to the fetus. Spontaneous abortions and congenital abnormalities have been suggested as potential risks associated with 150 mg of fluconazole as a single or repeated dose in the first trimester of pregnancy based on retrospective epidemiological studies.
There are no adequate and well-controlled studies of DIFLUCAN in pregnant women. (See WARNINGS: Potential for Fetal Harm.) Human Data Case reports describe a distinctive and rare pattern of birth defects among infants whose mothers received high-dose (400 to 800 mg/day) fluconazole during most or all of the first trimester of pregnancy.
The features seen in these infants include brachycephaly, abnormal facies, abnormal calvarial development, cleft palate, femoral bowing, thin ribs and long bones, arthrogryposis, and congenital heart disease. These effects are similar to those seen in animal studies. Epidemiological studies suggest a potential risk of spontaneous abortion and congenital abnormalities in infants whose mothers were treated with 150 mg of fluconazole as a single or repeated dose in the first trimester, but these epidemiological studies have limitations and these findings have not been confirmed in controlled clinical trials.
Animal Data Fluconazole was administered orally to pregnant rabbits during organogenesis in two studies at doses of 5 mg/kg, 10 mg/kg, and 20 mg/kg and at 5 mg/kg, 25 mg/kg, and 75 mg/kg, respectively. Maternal weight gain was impaired at all dose levels (approximately 0.25 to 4 times the 400 mg clinical dose based on body surface area [BSA] comparison), and abortions occurred at 75 mg/kg (approximately 4 times the 400 mg clinical dose based on BSA); no adverse fetal effects were observed.
In several studies in which pregnant rats received fluconazole orally during organogenesis, maternal weight gain was impaired and placental weights were increased at 25 mg/kg. There were no fetal effects at 5 mg/kg or 10 mg/kg; increases in fetal anatomical variants (supernumerary ribs, renal pelvis dilation) and delays in ossification were observed at 25 mg/kg and 50 mg/kg and higher doses.
At doses ranging from 80 to 320 mg/kg (approximately 2 to 8 times the 400 mg clinical dose based on BSA), embryolethality in rats was increased and fetal abnormalities included wavy ribs, cleft palate, and abnormal craniofacial ossification. These effects are consistent with the inhibition of estrogen synthesis in rats and may be a result of known effects of lowered estrogen on pregnancy, organogenesis, and parturition.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Fluconazole was present in low levels in breast milk following administration of a single 150 mg dose, based on data from a study in 10 breastfeeding women who temporarily or permanently discontinued breastfeeding 5 days to 19 months postpartum. The estimated daily infant dose of fluconazole from breast milk (assuming mean milk consumption of 150 mL/kg/day) based on the mean peak milk concentration (2.61 mcg/mL [range: 1.57 to 3.65 mcg/mL] at 5.2 hours post-dose) was 0.39 mg/kg/day, which is approximately 13% of the recommended pediatric dose for oropharyngeal candidiasis.
(Labeled pediatric dose is 6 mg/kg/day on the first day followed by 3 mg/kg/day; estimated infant dose is 13% of 3 mg/kg/day maintenance dose). There are no data on fluconazole levels in milk after repeated use or after high-dose fluconazole. A published survey of 96 breastfeeding women who were treated with fluconazole 150 mg every other day (average of 7.3 capsules [range 1 to 29 capsules]) for lactation-associated candida of the breasts reported no serious adverse reactions in infants.
Caution should be exercised when DIFLUCAN is administered to a nursing woman.
Mechanism of action
Mechanism of Action Fluconazole is a highly selective inhibitor of fungal cytochrome P450 dependent enzyme lanosterol 14-α-demethylase. This enzyme functions to convert lanosterol to ergosterol. The subsequent loss of normal sterols correlates with the accumulation of 14-α-methyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.
US FDA labelPharmacokinetics
Key PK parameters
| Bioavailability | Over 90% |
|---|---|
| Time to peak | 1 to 2 hours |
| Half-life | About 30 hours (20 to 50) |
| Half-life in kidney failure (ESKD) kidney | Prolonged; inversely related to CrCl (label) |
| Volume of distribution | About total body water |
| Protein binding | 11% to 12% |
| Metabolism (CYP, transporters) | Minimal |
| Active metabolites | None |
| Renal excretion kidney | About 80% unchanged in urine |
| Dialyzability kidney | Yes (about 50% per 3-hour session; label) |
Peak plasma concentrations (C max ) in fasted normal volunteers occur between 1 and 2 hours with a terminal plasma elimination half-life of approximately 30 hours (range: 20 to 50 hours) after oral administration.
(See DOSAGE AND ADMINISTRATION .) Table 1: Mean Pharmacokinetic Parameters of Fluconazole in Adult Healthy Volunteers Following the Administration of DIFLUCAN Dose regimen C max (mcg/mL) AUC 0-24 (mcg*h/mL) Half-life (hours) 50 mg oral (once daily x 7 days) 2.21 37.6 26.6 100 mg oral (once daily x 7 days) 4.81 82.5 27.7 150 mg single oral 2.70 137* 34.1 200 mg oral (once daily x 14 days) 10.12 169.5 31 300 mg oral (once daily x 14 days) 15.98 299.4 34 400 mg oral (once daily x 14 days) 18.89 349.9 31 *AUC 0-inf.
In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug.
About 11% of the dose is excreted in the urine as metabolites.
There is an inverse relationship between the elimination half-life and creatinine clearance.
Pharmacokinetics (US label) US FDA label
Pharmacokinetics and Metabolism The pharmacokinetic properties (PK) of fluconazole are similar following administration by the intravenous or oral routes. In normal volunteers, the bioavailability of orally administered fluconazole is over 90% compared with intravenous administration. Bioequivalence was established between the 100 mg tablet and both suspension strengths when administered as a single 200 mg dose.
Peak plasma concentrations (C max) in fasted normal volunteers occur between 1 and 2 hours with a terminal plasma elimination half-life of approximately 30 hours (range: 20 to 50 hours) after oral administration. In fasted normal volunteers, administration of a single oral 400 mg dose of DIFLUCAN (fluconazole) leads to a mean C max of 6.72 mcg/mL (range: 4.12 to 8.08 mcg/mL) and after single or multiple oral doses of 50 to 400 mg, fluconazole plasma concentrations and area under the plasma concentration time curve (AUC) are dose proportional (Table 1).
The C max and AUC data from a food-effect study involving administration of DIFLUCAN (fluconazole) tablets to healthy volunteers under fasting conditions and with a high-fat meal indicated that exposure to the drug is not affected by food. Therefore, DIFLUCAN may be taken without regard to meals. (See DOSAGE AND ADMINISTRATION.) Table 1: Mean Pharmacokinetic Parameters of Fluconazole in Adult Healthy Volunteers Following the Administration of DIFLUCAN Dose regimen C max (mcg/mL) AUC 0-24 (mcg*h/mL) Half-life (hours) 50 mg oral (once daily x 7 days) 2.21 37.6 26.6 100 mg oral (once daily x 7 days) 4.81 82.5 27.7 150 mg single oral 2.70 137* 34.1 200 mg oral (once daily x 14 days) 10.12 169.5 31 300 mg oral (once daily x 14 days) 15.98 299.4 34 400 mg oral (once daily x 14 days) 18.89 349.9 31 *AUC 0-inf.
Cmax= peak plasma concentrations, AUC =area under the plasma concentration time curve. Steady-state concentrations are reached within 5 to 10 days following oral doses of 50 to 400 mg given once daily. Administration of a loading dose (on Day 1) of twice the usual daily dose results in plasma concentrations close to steady-state by the second day.
The apparent volume of distribution of fluconazole approximates that of total body water. Plasma protein binding is low (11 to 12%). Following either single- or multiple oral doses for up to 14 days, fluconazole penetrates into all body fluids studied (see table below). In normal volunteers, saliva concentrations of fluconazole were equal to or slightly greater than plasma concentrations regardless of dose, route, or duration of dosing.
In patients with bronchiectasis, sputum concentrations of fluconazole following a single 150 mg oral dose were equal to plasma concentrations at both 4 and 24 hours post dose. In patients with fungal meningitis, fluconazole concentrations in the cerebrospinal fluid (CSF) are approximately 80% of the corresponding plasma concentrations.
A single oral 150 mg dose of fluconazole administered to 27 patients penetrated into vaginal tissue, resulting in tissue: plasma ratios ranging from 0.94 to 1.14 over the first 48 hours following dosing. A single oral 150 mg dose of fluconazole administered to 14 patients penetrated into vaginal fluid, resulting in fluid: plasma ratios ranging from 0.36 to 0.71 over the first 72 hours following dosing.
Table 2: Ratio of Fluconazole Tissue (Fluid)/Plasma Concentration Tissue or Fluid Ratio of Fluconazole Tissue (Fluid)/Plasma Concentration Relative to concurrent concentrations in plasma in subjects with normal renal function. Cerebrospinal fluid Independent of degree of meningeal inflammation. 0.5–0.9 Saliva 1 Sputum 1 Blister fluid 1 Urine 10 Normal skin 10 Nails 1 Blister skin 2 Vaginal tissue 1 Vaginal fluid 0.4–0.7 Mean body clearance in adults is reported to be 0.23 (17%) mL/min/kg.
In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug. About 11% of the dose is excreted in the urine as metabolites. The pharmacokinetics of fluconazole are markedly affected by reduction in renal function. There is an inverse relationship between the elimination half-life and creatinine clearance.
The dose of DIFLUCAN may need to be reduced in patients with impaired renal function. (See DOSAGE AND ADMINISTRATION.) A 3-hour hemodialysis session decreases plasma concentrations by approximately 50%. In normal volunteers, DIFLUCAN administration (doses ranging from 200 mg to 400 mg once daily for up to 14 days) was associated with small and inconsistent effects on testosterone concentrations, endogenous corticosteroid concentrations, and the adrenocorticotropic hormone (ACTH)-stimulated cortisol response.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Fluconazole 2 mg/mL, 100 mL Vial | ₱75.00–₱1,100.00Reference ₱312.34 | per vial | DPRI procurement range |
| Fluconazole 50 mg Capsule | ₱65.00–₱85.00Reference ₱69.40 | per capsule | DPRI procurement range |
| Fluconazole 150 mg Capsule | ₱29.42–₱184.62Reference ₱68.00 | per capsule | DPRI procurement range |
| Fluconazole 200 mg Capsule | ₱250.00–₱500.00Reference ₱278.00 | per capsule | DPRI procurement range |
| 50 mg capsule | ₱186.75 | per capsule | PhilHealth GAMOT fixed fee |
| 150 mg capsule | ₱375.00 | per capsule | PhilHealth GAMOT fixed fee |
| 200 mg capsule | ₱693.00 | per capsule | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Fluconazole |
| PNF listing | Oral: 50 mg, 150 mg and 200 mg capsule |
| PNF listing | Inj.: 2 mg/mL, 100 mL vial (IV infusion) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Diflucan · Roerig [US FDA-approved label, version 57, April 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f694c617-3383-416c-91b6-b94fda371204
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Roerig. (2026). DIFLUCAN (fluconazole) tablets, oral suspension and injection [Prescribing information; US FDA-approved label, NDA020090, set ID f694c617-3383-416c-91b6-b94fda371204, version effective April 2, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f694c617-3383-416c-91b6-b94fda371204
- Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
- Li, P. K., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y. L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .